Skip to main content

Table 4 Clinical, functional, and laboratory data presented as the difference between results at baseline and at 6 months according to prior biologic therapy use

From: Real-life experience with benralizumab during 6 months

Variables Biologic treatment-naïve patients
(n = 20)
Patients with prior biologic therapy
(n = 22)
p
Subjective improvement*, n (%) 20 (100) 18 (81.8) 0.487
Corticosteroid-dependent at 6 months, n (%) 4 (20) 4 (18.2) 0.125
ACT*, md (IR) 8 (5) 5.5 (4) 0.196
No. of ED visits at 6 months; md (IR) 1 (5) 2 (10) 1
Post-BD FEV1, mL*; md (IR) 330 (350) 238 (375) 0.279
Post-BD FEV1, %*; md (IR) 11 (8) 7.5 (15) 0.424
FeNO, ppb*; md (IR) 40 (28) 34 (45) 0.316
Blood eosinophil count, cells/μL*; md (IR) 755 (312) 692 (221) 0.274
  1. *Difference between results at baseline and at 6 months
  2. Abbreviations: ACT Asthma Control Test, BD Bronchodilator, ED Emergency department, FeNO Fractional exhaled nitric oxide, FEV1 Forced expiratory volume in 1 s, IR Interquartile range, md Median, ppb Parts per billion